Forest Alzheimer's drug development
Forest will submit NDA for memantine "around the end of 2001," but the company appears to view approval based on the two completed pivotal trials to be a long shot. FDA has agreed that the U.S. trial of memantine appears to support efficacy of the drug, but the agency "indicated that a second study performed in Europe would likely need to be reviewed by an advisory committee to determine whether the specific endpoints utilized were adequate to qualify it as a second study demonstrating efficacy," Forest said. The company is initiating additional Phase III studies in both mild-to-moderate and moderate-to-severe Alzheimer's in case additional evidence of efficacy is required. Forest hopes to launch the product "by the second half of 2003"; a decision by the advisory committee that the European study is sufficient would allow for an earlier launch
More from Archive
More from Pink Sheet
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.
Industry feedback on a European Medicines Agency pilot that introduced a “stepwise” approach to pediatric investigation plans was positive, but the future of the new model will depend on the outcome of the pharmaceutical legislation negotiations, the agency says.
All RSV vaccines with US FDA approval for high-risk younger adult patients will be incorporated in US CDC’s Advisory Committee for Immunization Practices recommendations. Merck’s infant RSV antibody is on track for a June vote